If this message does not display properly, please click here to launch your browser
|
— A Webinar from Decision Resources, Inc. | |||
Based on our U.S. Physician & Payer Forum report entitled Hospital Anti-Infectives: Insights on the Uptake, Formulary Inclusion, and Reimbursement of Emerging Antibiotics in the U.S. AND our Hospital Insight Series: Hospital Anti-Infectives report, Decision Resources, Inc. is offering this exclusive webinar. Because this presentation will feature major findings, it is ONLY available to purchasers of BOTH of these reports. Please contact us to learn how you can purchase both of these reports and attend the webinar. The anti-bacterial hospital market is crowded and dynamic as growing rates of antibiotic resistance continue to present commercial opportunities for novel agents. Drug development efforts are directed primarily towards addressing unmet needs in the treatment of methicillin-resistant Staphylococcus aureus (MRSA), Clostridium difficile infections and drug-resistant gram-negative pathogens. Although several emerging therapies target MRSA, the late-stage pipeline for gram-negative pathogens is dry and presents a significant market opportunity. Therapies that treat smaller and underserved difficult-to-treat infections such as prosthetic joint infections and sepsis also have important commercial potential. Surveyed infectious disease specialists and internists have revealed their preferred line of treatment for gram-positive and gram-negative infections, their choice of top attributes for difficult-to-treat infections and their anticipated use of key emerging therapies. Surveyed pharmacy directors have disclosed the most influential factors in the formulary inclusion of an antibiotic and the measures they consider in the decision for cost-effectiveness analysis. This webinar, presented by Decision Resources Analyst Charu Vepari, Ph.D., will answer the following questions:
Dr. Vepari will conduct a live Q & A session after the presentation. Hospital Antibiotics: What are the Leading Indications and Preferred Therapies for the Treatment of Key Pathogens, the Unmet Needs and the Drivers of Formulary Decisions? June 1, 2011 at 10 a.m. U.S. Eastern Time, 4 p.m. Central European Time (Paris). To learn how you can purchase these reports and attend the webinar, please contact us using the information below. In North America — Keith Rourke at 781-993-2656 or krourke@dresources.com |
|
||
|
|||
|
Terms of Use | Privacy Policy | Contact Us | Careers |
|||
Charu Vepari, Ph.D., is an analyst in the infectious diseases group at Decision Resources. Prior to joining the company, she served in several teaching roles, including as an instructor at Tufts University and as an adjunct professor of bioengineering at Olin College of Engineering, where she taught an undergraduate course on topics in bioengineering. Dr. Vepari also worked at Wyeth as a process development associate. Part of her duties there were to develop and validate purification processes of recombinant protein biologics and to support investigational new drug (IND) and biologics license application (BLA) filings. She earned a B.S. in biotechnology from Worcester Polytechnic Institute and a Ph.D. in chemical and bioengineering from Tufts University, where she studied special surface functionalization to control cell responses.
